BridgeBio Pharma (NASDAQ:BBIO) (NASDAQ: BBIO) is a biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers. Since its founding in 2015 by Neil Kumar, BridgeBio has built an integrated model that spans from early-stage research through late-stage development and manufacturing. Its core focus lies in identifying well-validated genetic targets and advancing therapies through clinical proof of concept, with the aim of delivering treatments that address the root causes of disease.
The company’s pipeline comprises a diverse array of programs in both rare and more prevalent indications. Key initiatives include investigational therapies for inherited cardiomyopathies, metabolic disorders, skeletal dysplasias, and oncogenic-driven tumors. Notable assets include acoramidis for transthyretin amyloid cardiomyopathy, infigratinib for cholangiocarcinoma, and fosdenopterin for molybdenum cofactor deficiency. BridgeBio’s work extends across small molecules, biologics and enzyme replacement therapies, reflecting its commitment to leveraging multiple modalities to tackle genetic dysfunction.
Headquartered in Palo Alto, California, BridgeBio maintains research and development operations in the United States and Europe, with additional hubs for chemistry, manufacturing, and controls. The company collaborates with academic institutions, patient advocacy groups, and strategic pharma partners to accelerate progress and ensure patient-centric development. BridgeBio’s in-house manufacturing capabilities enable scale-up of late-stage assets and support supply continuity, while partnerships facilitate access to specialized expertise and global networks.
Leadership at BridgeBio Pharma is spearheaded by co-founder and Chief Executive Officer Neil Kumar, whose background in private equity and biotech entrepreneurship has guided the organization’s integrated approach. The executive team includes seasoned professionals in clinical development, regulatory affairs, finance, and commercial strategy, all united by a mission to transform the lives of patients affected by genetic diseases. With a robust pipeline and a proven framework for rapid translation from gene to medicine, BridgeBio aims to bring meaningful therapies to the market and deliver long-term value to shareholders and the broader healthcare community.
